ESTABLISHMENT LABS HOLDINGS INC. (ESTA) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does ESTABLISHMENT LABS HOLDINGS INC. Do?
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica. ESTABLISHMENT LABS HOLDINGS INC. (ESTA) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Juan José Chacón Quirós and employs approximately 960 people. With a market capitalization of $1.7B, ESTA is one of the notable companies in the Healthcare sector.
ESTABLISHMENT LABS HOLDINGS INC. (ESTA) Stock Rating — Reduce (April 2026)
As of April 2026, ESTABLISHMENT LABS HOLDINGS INC. receives a Reduce rating with a composite score of 36.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ESTA ranks #2,880 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ESTABLISHMENT LABS HOLDINGS INC. ranks #404 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ESTA Stock Price and 52-Week Range
ESTABLISHMENT LABS HOLDINGS INC. (ESTA) currently trades at $60.19. The stock lost $1.87 (3.0%) in the most recent trading session. The 52-week high for ESTA is $83.31, which means the stock is currently trading -27.8% from its annual peak. The 52-week low is $26.55, putting the stock 126.7% above its annual trough. Recent trading volume was 355K shares, suggesting relatively thin trading activity.
Is ESTA Overvalued or Undervalued? — Valuation Analysis
ESTABLISHMENT LABS HOLDINGS INC. (ESTA) carries a value factor score of 31/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 73.48x, versus the sector average of 2.75x. The price-to-sales ratio is 9.27x, compared to 1.66x for the average Healthcare stock.
At current multiples, ESTABLISHMENT LABS HOLDINGS INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
ESTABLISHMENT LABS HOLDINGS INC. Profitability — ROE, Margins, and Quality Score
ESTABLISHMENT LABS HOLDINGS INC. (ESTA) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -276.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -18.2% versus the sector average of -33.1%.
On a margin basis, ESTABLISHMENT LABS HOLDINGS INC. reports gross margins of 67.5%, compared to 71.5% for the sector. The operating margin is -27.2% (sector: -66.1%). Net profit margin stands at -36.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 21.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
ESTA Debt, Balance Sheet, and Financial Health
ESTABLISHMENT LABS HOLDINGS INC. has a debt-to-equity ratio of 1417.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 3.04x, indicating strong short-term liquidity. Total debt on the balance sheet is $246M. Cash and equivalents stand at $71M.
ESTA has a beta of 1.84, meaning it is more volatile than the broader market — a $10,000 investment in ESTA would be expected to move 84.2% more than the S&P 500 on any given day. The stability factor score for ESTABLISHMENT LABS HOLDINGS INC. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
ESTABLISHMENT LABS HOLDINGS INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, ESTABLISHMENT LABS HOLDINGS INC. reported revenue of $187M and earnings per share (EPS) of $-1.72. Net income for the quarter was $-65M. Gross margin was 67.5%. Operating income came in at $-48M.
In FY 2025, ESTABLISHMENT LABS HOLDINGS INC. reported revenue of $211M and earnings per share (EPS) of $-1.72. Net income for the quarter was $-51M. Gross margin was 69.3%. Revenue grew 27.1% year-over-year compared to FY 2024. Operating income came in at $-39M.
In Q3 2025, ESTABLISHMENT LABS HOLDINGS INC. reported revenue of $54M and earnings per share (EPS) of $-0.38. Net income for the quarter was $-11M. Gross margin was 70.1%. Revenue grew 33.7% year-over-year compared to Q3 2024. Operating income came in at $-4M.
In Q2 2025, ESTABLISHMENT LABS HOLDINGS INC. reported revenue of $51M and earnings per share (EPS) of $-0.57. Net income for the quarter was $-17M. Gross margin was 68.8%. Revenue grew 16.3% year-over-year compared to Q2 2024. Operating income came in at $-14M.
Over the past 8 quarters, ESTABLISHMENT LABS HOLDINGS INC. has demonstrated a growth trajectory, with revenue expanding from $44M to $187M. Investors analyzing ESTA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ESTA Dividend Yield and Income Analysis
ESTABLISHMENT LABS HOLDINGS INC. (ESTA) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
ESTA Momentum and Technical Analysis Profile
ESTABLISHMENT LABS HOLDINGS INC. (ESTA) has a momentum factor score of 61/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 42/100 reflects moderate short selling activity.
ESTA vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, ESTABLISHMENT LABS HOLDINGS INC. (ESTA) ranks #404 out of 838 stocks based on the Blank Capital composite score. This places ESTA in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing ESTA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ESTA vs S&P 500 (SPY) comparison to assess how ESTABLISHMENT LABS HOLDINGS INC. stacks up against the broader market across all factor dimensions.
ESTA Next Earnings Date
No upcoming earnings date has been announced for ESTABLISHMENT LABS HOLDINGS INC. (ESTA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ESTA? — Investment Thesis Summary
The quantitative profile for ESTABLISHMENT LABS HOLDINGS INC. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 31/100 indicates premium valuation. Price momentum is positive at 61/100, suggesting the trend favors buyers. High volatility (stability score 35/100) increases portfolio risk.
In summary, ESTABLISHMENT LABS HOLDINGS INC. (ESTA) earns a Reduce rating with a composite score of 36.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ESTA stock.
Related Resources for ESTA Investors
Explore more research and tools: ESTA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ESTA head-to-head with peers: ESTA vs AZN, ESTA vs SLGL, ESTA vs VMD.